Popescu Gh. I. 1,2, Lupescu Olivera 1,2, Pătru Cristina 2, Nagea M. 2, Vasilache Cornelia 3,
Dimitriu Al. 4, Macovei R. Al. 1,2
1 Orthopedics and Trauma Clinic, Clinical Emergency Hospital Bucharest, Romania
2 University of Medicine and Pharmacy Bucharest
3 County Emergency Hospital Braila
Abstract
Rivaroxaban, a novel anti-thrombotic drug, has been described as having a highly potent activity on the coagulation mechanism, due to its reversible inhibiting action on the central point of the coagulation cascade, Factor Xa. Published studies reveal some advantages of Rivaroxaban compared to previously used anti-thrombotics: it is orally administered and rapidly absorbed and it allows a fixed dose regimen as its pharmacokinetic and pharmacodynamic profile is predictable. Having similar cardiovascular and hepatic side effects to other anti-thrombotic drugs and a low risk of bleeding, as shown by the published studies, Rivaroxaban can be considered well tolerated and effective in prevention of thrombembolic events. The authors present some aspects regarding their experience with this drug used in thrombo-prophylaxis following hip arthroplasty, a high thrombo-embolic risk procedure with increasing frequency in modern orthopedics. The results of this prospective study –post-operative blood loss, the incidence of thrombo-embolic events, side effects confirm the data presented in literature regarding the efficacy and safety of Rivaroxaban in major orthopedic surgery.